Hans Schreiber to T-Lymphocytes
This is a "connection" page, showing publications Hans Schreiber has written about T-Lymphocytes.
Connection Strength
2.095
-
Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors--letter. Cancer Res. 2014 Jan 15; 74(2):632; discussion 635.
Score: 0.260
-
Spleen cells from young but not old immunized mice eradicate large established cancers. Clin Cancer Res. 2012 May 01; 18(9):2526-33.
Score: 0.229
-
Cancer. Awakening immunity. Science. 2010 Nov 05; 330(6005):761-2.
Score: 0.208
-
Equilibrium between host and cancer caused by effector T cells killing tumor stroma. Cancer Res. 2008 Mar 01; 68(5):1563-71.
Score: 0.173
-
Selection of therapeutically effective T-cell receptors from the diverse tumor-bearing repertoire. J Immunother Cancer. 2025 May 02; 13(5).
Score: 0.142
-
Structure-guided engineering of the affinity and specificity of CARs against Tn-glycopeptides. Proc Natl Acad Sci U S A. 2020 06 30; 117(26):15148-15159.
Score: 0.101
-
Automated cell cluster analysis provides insight into multi-cell-type interactions between immune cells and their targets. Exp Cell Res. 2020 08 15; 393(2):112014.
Score: 0.101
-
Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells. Clin Cancer Res. 2020 02 01; 26(3):679-689.
Score: 0.097
-
TCR-pMHC bond conformation controls TCR ligand discrimination. Cell Mol Immunol. 2020 03; 17(3):203-217.
Score: 0.096
-
Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J Exp Med. 1997 Jul 21; 186(2):229-38.
Score: 0.083
-
Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma. Immunity. 2016 06 21; 44(6):1444-54.
Score: 0.077
-
Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc Natl Acad Sci U S A. 1995 Jul 03; 92(14):6254-8.
Score: 0.072
-
Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell. 2013 Apr 15; 23(4):516-26.
Score: 0.062
-
Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity. Proc Natl Acad Sci U S A. 1991 May 01; 88(9):3535-9.
Score: 0.054
-
Major histocompatibility complex class I and unique antigen expression by murine tumors that escaped from CD8+ T-cell-dependent surveillance. Cancer Res. 1990 Jul 01; 50(13):3851-8.
Score: 0.051
-
Specificity in cancer immunotherapy. Semin Immunol. 2008 Oct; 20(5):276-85.
Score: 0.045
-
IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J Clin Invest. 2008 Apr; 118(4):1398-404.
Score: 0.043
-
Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol. 2004 Dec; 14(6):433-9.
Score: 0.035
-
Long-term suppression of tumor growth by TNF requires a Stat1- and IFN regulatory factor 1-dependent IFN-gamma pathway but not IL-12 or IL-18. J Immunol. 2004 Mar 01; 172(5):3243-51.
Score: 0.033
-
Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol. 2004 Feb; 5(2):141-9.
Score: 0.032
-
Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model. J Immunother Cancer. 2023 05; 11(5).
Score: 0.031
-
Unique tumor antigens redefined as mutant tumor-specific antigens. Semin Immunol. 1996 Oct; 8(5):289-93.
Score: 0.020
-
Antigenic cancer cells that escape immune destruction are stimulated by host cells. Cancer Res. 1995 Nov 01; 55(21):5094-100.
Score: 0.018
-
Mechanism of tumor rejection in anti-CD3 monoclonal antibody-treated mice. J Immunol. 1990 Apr 01; 144(7):2840-6.
Score: 0.012
-
In vivo administration of anti-CD3 prevents malignant progressor tumor growth. Science. 1988 Oct 28; 242(4878):569-71.
Score: 0.011
-
Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol. 2007 Aug 01; 179(3):1960-8.
Score: 0.010